Qvar Redihaler is a drug owned by Norton Waterford Ltd. It is protected by 18 US drug patents filed from 2017 to 2024. Out of these, 16 drug patents are active and 2 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 19, 2041. Details of Qvar Redihaler's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11583643 | Inhalers and related methods |
Aug, 2041
(16 years from now) | Active |
| US11957832 | Breath actuated inhaler |
May, 2041
(15 years from now) | Active |
| US11559637 | Inhalers and related methods |
Jul, 2039
(14 years from now) | Active |
| US10792447 | Breath actuated inhaler |
Jan, 2039
(13 years from now) | Active |
| US11793953 | Inhalers and related methods |
Jan, 2038
(12 years from now) | Active |
| US11395888 | Inhalers and related methods |
Jan, 2038
(12 years from now) | Active |
| US11865247 | Inhalers and related methods |
Jan, 2038
(12 years from now) | Active |
| US11896759 | Inhalers and related methods |
Jan, 2038
(12 years from now) | Active |
| US10561808 | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(6 years from now) | Active |
| US8931476 | Inhaler |
Jul, 2031
(6 years from now) | Active |
| US10022510 | Dose counters for inhalers, inhalers and methods of assembly thereof |
May, 2031
(6 years from now) | Active |
| US10086156 | Dose counter for inhaler and method for counting doses |
May, 2031
(6 years from now) | Active |
| US10695512 | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | Active |
| US11395889 | Dose counter for inhaler having an anti-reverse rotation actuator |
May, 2031
(6 years from now) | Active |
| US10022509 | Dose counter for inhaler having a bore and shaft arrangement |
May, 2031
(6 years from now) | Active |
| US8132712 | Metered-dose inhaler |
Sep, 2028
(3 years from now) | Active |
| US7637260 | Medicament dispensing device with a multimaterial diaphragm bounding a pneumatic force chamber |
Aug, 2020
(4 years ago) |
Expired
|
| US6446627 | Inhaler dose counter |
Dec, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qvar Redihaler's patents.
Latest Legal Activities on Qvar Redihaler's Patents
Given below is the list of recent legal activities going on the following patents of Qvar Redihaler.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Mar, 2024 | US10792447 |
| Recordation of Patent Grant Mailed Critical | 13 Feb, 2024 | US11896759 |
| Recordation of Patent eGrant | 13 Feb, 2024 | US11896759 |
| Email Notification Critical | 13 Feb, 2024 | US11896759 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Feb, 2024 | US11896759 |
| Patent eGrant Notification | 13 Feb, 2024 | US11896759 |
| Mail Patent eGrant Notification | 13 Feb, 2024 | US11896759 |
| Email Notification Critical | 25 Jan, 2024 | US11896759 |
| Issue Notification Mailed Critical | 24 Jan, 2024 | US11896759 |
| Dispatch to FDC | 16 Jan, 2024 | US11896759 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Qvar Redihaler and ongoing litigations to help you estimate the early arrival of Qvar Redihaler generic.
Qvar Redihaler's Litigations
Qvar Redihaler been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Qvar Redihaler's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10561808 | October, 2018 |
Decision
(20 Sep, 2019) | Declan Walsh et al. | |
US patents provide insights into the exclusivity only within the United States, but Qvar Redihaler is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qvar Redihaler's family patents as well as insights into ongoing legal events on those patents.
Qvar Redihaler's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Qvar Redihaler's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 19, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Qvar Redihaler Generics:
There are no approved generic versions for Qvar Redihaler as of now.
Alternative Brands for Qvar Redihaler
There are several other brand drugs using the same active ingredient (Beclomethasone Dipropionate) as Qvar Redihaler. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Qvar Redihaler
Qvar Redihaler is a drug owned by Norton Waterford Ltd. Qvar Redihaler uses Beclomethasone Dipropionate as an active ingredient. Qvar Redihaler was launched by Norton Waterford in 2017.
Approval Date:
Qvar Redihaler was approved by FDA for market use on 03 August, 2017.
Active Ingredient:
Qvar Redihaler uses Beclomethasone Dipropionate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate ingredient
Dosage:
Qvar Redihaler is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.04MG/INH | AEROSOL, METERED | Prescription | INHALATION |
| 0.08MG/INH | AEROSOL, METERED | Prescription | INHALATION |